Revolution Medicines

$40.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.75 (+1.87%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RVMD and other stocks, options, and ETFs commission-free!

About RVMD

Revolution Medicines, Inc. Common Stock, also called Revolution Medicines, is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA. The listed name for RVMD is Revolution Medicines, Inc. Common Stock.

CEO
Mark A. Goldsmith
Employees
95
Headquarters
Redwood City, California
Founded
2015
Market Cap
2.59B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
488.61K
High Today
$41.44
Low Today
$39.01
Open Price
$39.58
Volume
824.73K
52 Week High
$47.83
52 Week Low
$17.35

Collections

RVMD Earnings

-$0.74
-$0.49
-$0.25
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
—

You May Also Like

AUGZ
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure